Vectus Biosystems Ltd
Vectus Biosystems Limited is an Australia-based drug discovery and development company.
The business
Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.
Small Caps Research
No research on Vectus Biosystems Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise VBS based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Vectus Biosystems launches $4.5m capital raising to advance anti-fibrosis drug
Drug discovery and development company Vectus Biosystems (ASX: VBS) has launched a $4.5 million capital raising to accelerate a phase 1b clinical trial of lead candidate VB0004 to treat fibrosis and hypertension. The raising will be conducted in two transactions, as a share placement to sophisticated investors and a share purchase plan to existing shareholders. […]
Vectus Biosystems progresses clinical trials of drug VB0004 for treating fibrosis and hypertension
Fibrotic diseases specialist Vectus Biosystems (ASX: VBS) has confirmed that it will move to the next phase of testing of its lead drug for treating fibrosis and hypertension. In its September quarter report, the company says phase 1a clinical trials to date have established an “impressive safety profile” for the drug candidate VB0004, with consistent […]
Vectus Biosystems moves to phase 1b in drug trial to treat fibrosis and hypertension
Biotechnology company Vectus Biosystems (ASX: VBS) has announced the completion of its phase 1a study of lead drug candidate VB0004 to treat fibrosis and hypertension. It had been the company’s first in-human trial to evaluate the safety, tolerability, and pharmacokinetics of single and repeated doses of the drug in healthy volunteers, as well as patients […]
Vectus Biosystems unveils more promising results from phase 1 clinical trial
Ahead of enticing pharmaceutical partners, Vectus Biosystems (ASX: VBS) is confident that positive results will continue to flow from the ongoing phase 1 trial of its lead drug VB0004 which treats fibrosis and high blood pressure. The biotechnology company has developed its lead compound VB0004 as a treatment for hypertension (high blood pressure) and fibrosis […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.